3 ASX Penny Stocks With Market Caps Under A$4B

Over the last 7 days, the Australian market has risen by 1.4%, although its performance over the past year has been flat, with earnings forecasted to grow annually by 11%. In light of these conditions, investors may find value in exploring penny stocks—an investment area often associated with smaller or newer companies that offer growth potential at lower price points. Despite their somewhat outdated name, penny stocks can still provide opportunities for growth when backed by strong financials and solid fundamentals.

Let's explore several standout options from the results in the screener.

Artrya (ASX:AYA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Artrya Limited is a medical technology company focused on developing and commercializing an artificial intelligence platform for detecting, diagnosing, and addressing coronary artery disease in Australia, with a market cap of A$451.41 million.

Operations: The company's revenue is derived from the development of AI-driven CCTA image analysis technology, amounting to A$0.03 million.

Market Cap: A$451.41M

Artrya Limited, with a market cap of A$451.41 million, is pre-revenue, generating only A$0.03 million from its AI-driven CCTA image analysis technology. Despite being unprofitable and having increased losses over the past five years, Artrya has a robust cash runway exceeding three years and no debt obligations. The company recently joined several indices including the S&P/ASX 300 Index, reflecting growing recognition in the market. The addition of Helen Kurincic to the board brings seasoned leadership with extensive healthcare experience that could be pivotal for future strategic direction and governance improvements.

• Click here to discover the nuances of Artrya with our detailed analytical financial health report.
• Evaluate Artrya's prospects by accessing our earnings growth report.

IGO (ASX:IGO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: IGO Limited, along with its subsidiaries, is involved in the discovery, development, and delivery of battery minerals in Australia with a market capitalization of A$3.76 billion.

Operations: The company's revenue is primarily generated from the Nova Operation, which accounts for A$448.9 million, and supplemented by interest revenue of A$14 million.

Market Cap: A$3.76B

IGO Limited, with a market cap of A$3.76 billion, recently became profitable, reporting net income of A$145.3 million for the year ended June 30, 2026. Despite a decline in earnings over the past five years and large one-off items impacting recent results, IGO's financial stability is underscored by its debt-free status and strong asset coverage for liabilities. The company announced an annual dividend of A$0.05 per share and has seen changes in board composition with the appointment of Ms Anthea McKinnell as Non-Executive Director to enhance governance amidst ongoing strategic developments in battery minerals production.

• Take a closer look at IGO's potential here in our financial health report.
• Examine IGO's earnings growth report to understand how analysts expect it to perform.

Perenti (ASX:PRN)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Perenti Limited is a global mining services company with a market capitalization of A$1.84 billion.

Operations: The company's revenue is derived from Drilling Services (A$842.72 million), Contract Mining Services (A$2.43 billion), and Mining and Technology Services (A$79.13 million).

Market Cap: A$1.84B

Perenti Limited, with a market cap of A$1.84 billion, has seen its debt-to-equity ratio improve from 53.5% to 30% over five years, indicating better financial management. Despite a drop in net income to A$18.76 million for the year ended June 30, 2026, and negative earnings growth of -33.8%, the company maintains satisfactory debt levels with operating cash flow covering 80.8% of its debt obligations. The firm has announced a share buyback program for up to 9.03% of its issued capital and increased dividends by 7%, reflecting confidence in future performance despite recent volatility and one-off losses impacting results.

• Unlock comprehensive insights into our analysis of Perenti stock in this financial health report.
• Learn about Perenti's future growth trajectory here.

Summing It All Up

• Embark on your investment journey to our 440 ASX Penny Stocks selection here.
• Seeking Other Investments? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com